MentionFox
Home › Stakes › Avenue Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Avenue Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of Avenue Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more1
Filings2
Latest filing2026-02-17

Avenue Therapeutics, Inc. has 2 Schedule 13D or 13G filings on record since 2026-01-06. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Fortress Biotech, Inc.13.4%439,955SCHEDULE 13D/A, 2026-01-062026-01-02
Ikarian Capital, LLC4.1%130,820SCHEDULE 13G/A, 2026-02-172025-12-31

Purpose of Transaction (Item 4)

Fortress Biotech, Inc.

The Reporting Person is party to that certain Second Amended and Restated Founders Agreement with the Issuer (as amended, the "Founders Agreement"), in connection with the Issuer's formation. Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Charter"), the Issuer issues annually to the Reporting Person shares of common stock equal to two and one-half percent (2.5%) of the fully-diluted outstanding equity of the Issuer, as measured as of the date of such issuance (the "Annual Equity Grant"). The foregoing description of the Charter and Founders Agreement are qualified in its entirety by reference to the full text of the Charter and Founders Agreement which are incorporated herein by reference as Exhibits 7.01 and 7.03.Item 4 of the SCHEDULE 13D/A filed 2026-01-06

Timeline

FiledHolderPercentFiling
2026-01-06Fortress Biotech, Inc.13.4%SCHEDULE 13D/A
2026-02-17Ikarian Capital, LLC4.1%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Avenue Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/avenue-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Avenue Therapeutics, Inc. 5%+ holders: 1 at 5% or more, largest Fortress Biotech, Inc. 13.4%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/avenue-therapeutics